Main Menu
Search

22 June 2015

New era in pharma growth

Innovation and technology key to growth of pharma companies in emerging markets

Emerging markets are predicted to account for a third of global pharmaceutical spend by the end of next year – and seen as critical for the sustained growth of leading pharma companies. That’s according to a new report, which says innovation and technology will be important differentiators as pharma organisations try to drive growth in developing countries.

The report summarises the findings of a Cambridge Consultants workshop held in Mumbai, India, earlier this year. The product design and development firm brought together senior personnel from both Indian and multinational pharma companies to debate whether emerging markets can be an opportunity to drive sustainable growth.

The consensus was that the term ‘emerging markets' covers nations in parts of Africa, the Middle East and South East Asia, as well as the more traditional countries of Brazil, Russia, India and China. But all the delegates said emerging markets cannot be grouped into a single cluster to chalk out common strategies. Clustering markets around parameters such as regulatory pathways or therapeutic applications was considered the best approach.

"Emerging markets are facing rapid growth of chronic 'Western' diseases like diabetes, hypertension, chronic respiratory problems, cancer, heart disease and neurological disorders," said Ambuj Jain, India general manager at Cambridge Consultants. "In some cases, conditions like diabetes are turning into near-epidemic situations.

"In India, for example, the prevalence of diabetes and cancer is projected to rise by 25-40% over the next 10 years. This shift gives pharma companies an opportunity to market their global products in emerging markets, backed by tested ‘go-to-market’ strategies and operating models."

The report says key barriers which need to be addressed in many emerging markets are the affordability and accessibility of medicines. Improvements in affordability will be driven by rising disposable incomes and increasing insurance coverage. Growth in accessibility will come from increases in government spending and medical infrastructure, and new business models for rural areas. The acceptability of medicines is also expected to rise, as a result of the growth in chronic conditions – and the resulting increase in the self-administration of drugs.

Workshop delegate Sanjay Bhanushali, a director of global pharma company Cipla, said: "Emerging markets are critical for the sustained growth of leading pharmaceutical organisations. They represent a significant proportion of the world’s population and many of their governments are increasingly focusing on improving healthcare. Innovation and technology – with the emphasis on patient and stakeholder needs – will be crucial to success in these markets."

Diagnostics was seen by the workshop delegates as a key focus area where innovation can drive sustained growth. One of the problems is a shortage of diagnostics laboratories. Physicians often prescribe an empirical therapy because the cost of diagnosis is much higher than the cost of the therapy. For example, antibiotics are commonly prescribed for respiratory infections – where the causative pathogen may actually be a virus.

But the idea that healthcare innovation in emerging markets has to focus only on cost reduction was dismissed by the pharma experts. The example of smartphones was highlighted – how their adoption has penetrated all levels of society. This suggests that ‘value’, at the right price point, is more relevant in driving adoption of new technologies.

To request a copy of the workshop report – Emerging markets: an opportunity for pharma to drive sustainable growth – visit: www.cambridgeconsultants.com/2015-india-workshop-report

Notes to editors

Cambridge Consultants develops breakthrough products, creates and licenses intellectual property, and provides business consultancy in technology-critical issues for clients worldwide. For more than 50 years, the company has been helping its clients turn business opportunities into commercial successes, whether they are launching first-to-market products, entering new markets or expanding existing markets through the introduction of new technologies. With a team of more than 700 staff, including engineers, scientists, mathematicians and designers, in offices in Cambridge (UK), Boston (USA) and Singapore, Cambridge Consultants offers solutions across a diverse range of industries including medical technology, industrial and consumer products, digital health, oil and gas, and wireless communications.

Cambridge Consultants is part of Altran, a global leader in engineering and R&D services which offers its clients a new way to innovate. Altran works alongside its clients on every link in the value chain of their project, from conception to industrialisation. In 2015, the Altran group generated revenues of €1.945bn. With a headcount of more than 27,000 employees, Altran is present in more than 20 countries. For more information, visit www.altran.com.

Press Contacts

Corporate communications
Debbie Mayhew
PR & Communications Manager
Cambridge Consultants
+44 1223 392418
Debbie.Mayhew@CambridgeConsultants.com

European PR agency
David Vindel
Ketchum
+44 20 3755 6444
CambridgeConsultants@ketchum.com

US PR agency
Hanah Johnson
March Communications
+1 617 960 8892
CambridgeConsultants@ketchum.com